Jefferies backs Hansa Biopharma on U.S. launch hopes after trial success By Investing.com
Update: 2025-10-29
Description
**Summary:**Hansa Biopharma's enzyme therapy, Idefirix, gains significant traction with a buy rating and price target of 100 Swedish krona from Jefferies. Idefirix, used for highly sensitized kidney transplant patients, received EU approval and is reimbursed in 20 countries. A U.S. trial showed improved kidney function and reduced dialysis needs, paving the way for potential U.S. approval by 2026. With a strong cash position and potential for $600 million annual sales by 2034, Idefirix could revolutionize kidney transplantation.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
